MA33909B1 - Pyrrolidinones accoles en tant d'inhibiteurs de syk - Google Patents

Pyrrolidinones accoles en tant d'inhibiteurs de syk

Info

Publication number
MA33909B1
MA33909B1 MA35044A MA35044A MA33909B1 MA 33909 B1 MA33909 B1 MA 33909B1 MA 35044 A MA35044 A MA 35044A MA 35044 A MA35044 A MA 35044A MA 33909 B1 MA33909 B1 MA 33909B1
Authority
MA
Morocco
Prior art keywords
pyrolidine
adherent
disorders
diseases
compounds
Prior art date
Application number
MA35044A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Yasuyoshi Arikawa
Benjamin Jones
Betty Lam
Zhe Nie
Christopher Smith
Masashi Takahashi
Qing Dong
Victoria Feher
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43618073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33909(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA33909B1 publication Critical patent/MA33909B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
MA35044A 2009-12-23 2010-12-17 Pyrrolidinones accoles en tant d'inhibiteurs de syk MA33909B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28996909P 2009-12-23 2009-12-23
US38696410P 2010-09-27 2010-09-27
PCT/US2010/061146 WO2011079051A1 (en) 2009-12-23 2010-12-17 Fused heteroaromatic pyrrolidinones as syk inhibitors

Publications (1)

Publication Number Publication Date
MA33909B1 true MA33909B1 (fr) 2013-01-02

Family

ID=43618073

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35044A MA33909B1 (fr) 2009-12-23 2010-12-17 Pyrrolidinones accoles en tant d'inhibiteurs de syk

Country Status (42)

Country Link
US (7) US8440689B2 (enExample)
EP (4) EP3825316A1 (enExample)
JP (7) JP5658274B2 (enExample)
KR (1) KR101790255B1 (enExample)
CN (1) CN102753548B (enExample)
AR (1) AR081797A1 (enExample)
AU (1) AU2010333804B2 (enExample)
BR (1) BR112012015651B1 (enExample)
CA (1) CA2786950C (enExample)
CL (1) CL2012001745A1 (enExample)
CO (1) CO6592058A2 (enExample)
CR (1) CR20120392A (enExample)
CY (1) CY1116736T1 (enExample)
DK (1) DK2516434T3 (enExample)
DO (1) DOP2012000180A (enExample)
EA (1) EA021568B1 (enExample)
EC (1) ECSP12012057A (enExample)
ES (1) ES2545616T3 (enExample)
GE (1) GEP20156243B (enExample)
HR (1) HRP20150878T1 (enExample)
HU (1) HUE025177T2 (enExample)
IL (1) IL220509A (enExample)
JO (1) JO3108B1 (enExample)
MA (1) MA33909B1 (enExample)
ME (1) ME02186B (enExample)
MX (1) MX2012007402A (enExample)
MY (1) MY159257A (enExample)
NZ (1) NZ601267A (enExample)
PE (1) PE20130188A1 (enExample)
PH (1) PH12012501311A1 (enExample)
PL (1) PL2516434T3 (enExample)
PT (1) PT2516434E (enExample)
RS (1) RS54180B1 (enExample)
SG (1) SG181857A1 (enExample)
SI (1) SI2516434T1 (enExample)
SM (1) SMT201500199B (enExample)
TN (1) TN2012000316A1 (enExample)
TW (1) TWI457339B (enExample)
UA (1) UA107100C2 (enExample)
UY (1) UY33151A (enExample)
WO (1) WO2011079051A1 (enExample)
ZA (1) ZA201205428B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
SG181857A1 (en) * 2009-12-23 2012-07-30 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors
JP6001048B2 (ja) * 2011-03-28 2016-10-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ チアゾロピリミジン化合物
US9056873B2 (en) 2011-06-22 2015-06-16 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
EP2900243A4 (en) 2012-09-27 2016-04-13 Portola Pharm Inc BICYCLIC OXA LACTAM KINASE HEMMER
EP2900639B1 (en) * 2012-09-27 2017-08-16 Portola Pharmaceuticals, Inc. Bicyclic dihydropyridone kinase inhibitors
WO2014071109A1 (en) 2012-11-01 2014-05-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US20140377258A1 (en) 2013-05-30 2014-12-25 Infinity Pharmaceuticals, Inc. Treatment Of Cancers Using PI3 Kinase Isoform Modulators
AU2014296184B2 (en) 2013-07-31 2017-04-27 Gilead Sciences, Inc. Syk inhibitors
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
ES2921874T3 (es) * 2014-02-28 2022-09-01 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
CN113620958A (zh) 2014-03-19 2021-11-09 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
US10245262B2 (en) 2014-04-01 2019-04-02 The University Of Queensland Immunological reagents and uses therefor
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
KR20170090476A (ko) * 2014-12-05 2017-08-07 어레이 바이오파마 인크. 야누스 키나제 저해제로서의 4,6-치환된-피라졸로[1,5-a]피라진
PL3233857T3 (pl) * 2014-12-18 2020-07-27 Takeda Pharmaceutical Company Limited Stałe postacie skondensowanych heteroaromatycznych pirolidynonów
ES2930585T3 (es) 2015-02-27 2022-12-19 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
US10023571B2 (en) * 2015-09-02 2018-07-17 Nimbus Lakshimi, Inc. TYK2 inhibitors and uses thereof
PH12018500554B1 (en) 2015-09-14 2024-01-24 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
GB201604970D0 (en) 2016-03-23 2016-05-04 Syngenta Participations Ag Improvements in or relating to organic compounds
WO2017205801A1 (en) * 2016-05-27 2017-11-30 Takeda Pharmaceutical Company Limited Combination of immunotherapy agents and spleen tyrosine kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20190971A1 (es) 2016-06-13 2019-07-09 Glaxosmithkline Ip Dev Ltd Compuestos quimicos
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
JP2019520419A (ja) * 2016-07-13 2019-07-18 武田薬品工業株式会社 脾臓チロシンキナーゼ阻害剤と他の治療薬の併用
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
CA3036384A1 (en) 2016-09-14 2018-03-22 Gilead Sciences, Inc. Syk inhibitors
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
ES2906205T3 (es) * 2017-06-14 2022-04-13 Chia Tai Tianqing Pharmaceutical Group Co Ltd Inhibidor de Syk y método de uso para el mismo
TWI782056B (zh) * 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
US11174254B2 (en) 2017-09-28 2021-11-16 Yangtze River Pharmaceutical Group Co., Ltd. Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
SG11202002475TA (en) * 2017-10-19 2020-04-29 Bayer Animal Health Gmbh Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
WO2019088039A1 (en) 2017-10-30 2019-05-09 Takeda Pharmaceutical Company Limited Treatment of acute myeloid leukemia
CN111295384B (zh) * 2018-10-10 2022-08-12 江苏豪森药业集团有限公司 双环类衍生物抑制剂、其制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
JP7608166B2 (ja) 2019-01-11 2025-01-06 塩野義製薬株式会社 Ｍｇａｔ２阻害活性を有するジヒドロピラゾロピラジノン誘導体
JP2022521413A (ja) * 2019-02-22 2022-04-07 クロノス バイオ インコーポレイテッド Ｓｙｋ阻害剤としての縮合ピラジンの固体形態
WO2020187267A1 (zh) * 2019-03-18 2020-09-24 上海海雁医药科技有限公司 Btk抑制剂及其药学上可接受的盐和多晶型物及其应用
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022048551A1 (zh) * 2020-09-01 2022-03-10 上海海雁医药科技有限公司 布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用
CN115698005B (zh) * 2020-12-18 2024-02-06 山东轩竹医药科技有限公司 稠环类AhR抑制剂
US20240174662A1 (en) * 2021-02-01 2024-05-30 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
CN117120090A (zh) 2021-02-12 2023-11-24 林伯士萨顿公司 Hpk1拮抗剂和其用途
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
EP4313989A4 (en) 2021-03-29 2025-03-05 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
JP2024540296A (ja) * 2021-11-04 2024-10-31 レデックス・ファーマ・リミテッド 線維症
CN114907992B (zh) 2022-05-18 2023-06-16 塔里木大学 拮抗植物病原菌的菌株c11及其应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63107966A (ja) 1986-05-22 1988-05-12 Fujisawa Pharmaceut Co Ltd ピリミジン誘導体
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP1054004B1 (en) * 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
WO1999032479A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparation and their use as muscarinic receptor (ant-)agonists
EP1184376B1 (en) 1999-06-09 2005-02-02 Yamanouchi Pharmaceutical Co. Ltd. Novel heterocyclic carboxamide derivatives
FR2796946A1 (fr) 1999-07-30 2001-02-02 Aventis Pharma Sa Nouveaux derives 8-carbonyl chromanes, leur preparation et leur utilisation en therapeutique
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
EP1250128A2 (en) 1999-12-16 2002-10-23 Alcon, Inc. Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
EP1244668B1 (en) 2000-01-07 2006-04-05 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
AU2001232271A1 (en) 2000-02-14 2001-08-20 Japan Tobacco Inc. Preventives/remedies for postoperative stress
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
US7105667B2 (en) * 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003009852A1 (en) 2001-07-24 2003-02-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US20030158195A1 (en) 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
MXPA05001804A (es) 2002-08-14 2005-05-27 Vertex Pharma Inhibidores de proteinas cinasas y usos de los mismos.
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
AU2003286895A1 (en) 2002-11-05 2004-06-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
EP1610793A2 (en) 2003-03-25 2006-01-04 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
KR20050122220A (ko) 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 디펩티딜 펩티다제 억제제
CA2523126A1 (en) 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
US8178671B2 (en) 2003-07-30 2012-05-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050182061A1 (en) 2003-10-02 2005-08-18 Jeremy Green Phthalimide compounds useful as protein kinase inhibitors
JP4768628B2 (ja) * 2003-11-19 2011-09-07 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋの二環系阻害剤及びその使用方法
WO2005056524A2 (en) 2003-12-09 2005-06-23 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US8057815B2 (en) * 2004-04-19 2011-11-15 Portola Pharmaceuticals, Inc. Methods of treatment with Syk inhibitors
JP2008511659A (ja) 2004-09-01 2008-04-17 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物の合成
EP1814878B1 (en) 2004-11-24 2012-01-04 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
US20060128710A1 (en) 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
KR100926399B1 (ko) 2005-04-06 2009-11-12 아이알엠 엘엘씨 디아릴아민―함유 화합물 및 조성물, 및 스테로이드 호르몬핵 수용체의 조절제로서의 그들의 용도
US7745641B2 (en) * 2005-04-19 2010-06-29 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compound
WO2006129100A1 (en) 2005-06-03 2006-12-07 Glaxo Group Limited Novel compounds
CA2608476A1 (en) 2005-06-28 2007-01-04 Bausch & Lomb Incorporated Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells
AR056191A1 (es) 2005-08-23 2007-09-26 Idenix Phatmaceuticals Inc Anillo de nucleosidos de siete miembros como inhibidores de la replica viral, metodos para su sintesis, composiciones farmaceuticas que los contienen y su uso en el tratamiento de infecciones con virus de la familia flaviviridae
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
WO2007042298A1 (en) * 2005-10-13 2007-04-19 Glaxo Group Limited Pyrrolopyrimidine derivatives as syk inhibitors
US20070117775A1 (en) 2005-10-31 2007-05-24 Rigel Pharmaceuticals, Inc. Compositions and Methods For Treating Inflammatory Disorders
WO2007070872A1 (en) * 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
EP2537849A3 (en) 2006-01-17 2013-04-03 Vertex Pharmaceuticals, Inc. Azaindoles useful as inhibitors of janus kinases
CL2007002617A1 (es) 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
EP2108642A1 (en) 2006-10-17 2009-10-14 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
MX2009004077A (es) 2006-10-19 2009-05-05 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
JP5264759B2 (ja) 2006-11-21 2013-08-14 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物のプロドラッグ塩およびそれらの使用
JPWO2008081928A1 (ja) * 2006-12-28 2010-04-30 大正製薬株式会社 ピラゾロピリミジン化合物
WO2008100715A1 (en) * 2007-02-09 2008-08-21 Astrazeneca Ab Aza-isoindolones and their use as metabotropic glutamate receptor potentiators - 613
JP2010522174A (ja) 2007-03-23 2010-07-01 シェーリング コーポレイション Ｈｃｖｎｓ３−プロテアーゼ阻害剤としてのヒドラジド−ペプチド
EP2162136A4 (en) 2007-06-03 2012-02-15 Univ Vanderbilt GLUTAMATE METABOTROPIC POSITIVE RECEPTOR-BASED ALLOSTERIC-MODULATOR BENZAMIDE DERIVATIVES (MGLUR5) AND METHODS OF MAKING AND USING THEM
WO2009026107A1 (en) 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
JP2009067729A (ja) 2007-09-14 2009-04-02 Kyowa Hakko Kirin Co Ltd Ｈｓｐ９０ファミリー蛋白質阻害剤
CA2705303A1 (en) 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
WO2009080638A2 (en) 2007-12-20 2009-07-02 Cellzome Limited Sulfamides as zap-70 inhibitors
TW200942537A (en) * 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
JP5496915B2 (ja) 2008-02-13 2014-05-21 シージーアイ ファーマシューティカルズ，インコーポレーテッド ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法
AU2009215430B2 (en) 2008-02-22 2015-02-12 Rigel Pharmaceuticals, Inc. Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
KR101773313B1 (ko) 2008-04-16 2017-08-31 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
WO2009145856A1 (en) 2008-04-16 2009-12-03 Portola Pharmaceuticals, Inc. 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors
EP2310381A1 (en) 2008-06-13 2011-04-20 Novartis AG 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer
WO2010015518A2 (de) 2008-08-05 2010-02-11 Boehringer Ingelheim Interntional Gmbh 4-dimethylamino-phenyl-substituierte naphthyridine und ihre verwendung als arzneimittel
WO2010015520A1 (de) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituierte naphthyridine und ihre verwendung als arzneimittel
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
EP3552607A3 (en) 2008-12-08 2020-01-15 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
EP2443106A1 (en) 2009-06-18 2012-04-25 Cellzome Limited Heterocyclylaminopyrimidines as kinase inhibitors
EP2512246B1 (en) 2009-12-17 2015-09-30 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
MX2012007154A (es) 2009-12-17 2012-08-01 Merck Sharp & Dohme Aminopirimidinas como inhibidores de syk.
SG181857A1 (en) * 2009-12-23 2012-07-30 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
US9056873B2 (en) 2011-06-22 2015-06-16 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives

Also Published As

Publication number Publication date
HRP20150878T1 (xx) 2015-09-25
US9181255B2 (en) 2015-11-10
ME02186B (me) 2016-02-20
CA2786950A1 (en) 2011-06-30
PT2516434E (pt) 2015-10-05
EP3489236B1 (en) 2020-09-30
US9108970B2 (en) 2015-08-18
GEP20156243B (en) 2015-02-10
SI2516434T1 (sl) 2015-10-30
US20180141951A1 (en) 2018-05-24
CR20120392A (es) 2012-12-27
RS54180B1 (sr) 2015-12-31
TWI457339B (zh) 2014-10-21
UA107100C2 (xx) 2014-11-25
ZA201205428B (en) 2013-09-25
JP2017008052A (ja) 2017-01-12
PL2516434T3 (pl) 2015-11-30
JP2022110135A (ja) 2022-07-28
US20110152273A1 (en) 2011-06-23
JP6196710B2 (ja) 2017-09-13
EP3825316A1 (en) 2021-05-26
EA201290555A1 (ru) 2013-01-30
HK1176054A1 (en) 2013-07-19
EP2516434A1 (en) 2012-10-31
CA2786950C (en) 2019-01-15
HUE025177T2 (en) 2016-02-29
MX2012007402A (es) 2012-08-23
JO3108B1 (ar) 2017-09-20
CN102753548A (zh) 2012-10-24
PE20130188A1 (es) 2013-02-21
DOP2012000180A (es) 2012-09-15
JP2013515729A (ja) 2013-05-09
EP2902392A1 (en) 2015-08-05
TN2012000316A1 (en) 2013-12-12
KR101790255B1 (ko) 2017-10-26
US20150336964A1 (en) 2015-11-26
PH12012501311A1 (en) 2016-07-22
DK2516434T3 (en) 2015-08-31
CN102753548B (zh) 2015-03-11
JP2019056000A (ja) 2019-04-11
WO2011079051A1 (en) 2011-06-30
TW201127839A (en) 2011-08-16
CO6592058A2 (es) 2013-01-02
EP2516434B1 (en) 2015-05-27
AU2010333804A1 (en) 2012-07-26
JP5658274B2 (ja) 2015-01-21
IL220509A (en) 2016-07-31
UY33151A (es) 2011-07-29
AR081797A1 (es) 2012-10-24
NZ601267A (en) 2014-03-28
CY1116736T1 (el) 2017-03-15
EA021568B1 (ru) 2015-07-30
MY159257A (en) 2016-12-30
SMT201500199B (it) 2015-10-30
EP3489236A1 (en) 2019-05-29
ES2545616T3 (es) 2015-09-14
JP5968983B2 (ja) 2016-08-10
US8440689B2 (en) 2013-05-14
AU2010333804B2 (en) 2015-07-16
JP2015091815A (ja) 2015-05-14
EP2902392B1 (en) 2018-10-17
US20230295171A1 (en) 2023-09-21
JP2020164537A (ja) 2020-10-08
SG181857A1 (en) 2012-07-30
US20130245031A1 (en) 2013-09-19
CL2012001745A1 (es) 2014-07-18
BR112012015651A2 (pt) 2017-09-26
BR112012015651B1 (pt) 2021-10-26
US20220306634A1 (en) 2022-09-29
US20130116260A1 (en) 2013-05-09
ECSP12012057A (es) 2012-10-30
JP2018009017A (ja) 2018-01-18
KR20120124417A (ko) 2012-11-13

Similar Documents

Publication Publication Date Title
MA33909B1 (fr) Pyrrolidinones accoles en tant d'inhibiteurs de syk
GEP20146125B (en) Aminopyrimidines as syk inhibitors
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
GEP20166484B (en) Protein kinase inhibitors
MX368781B (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
MX2014000130A (es) Procedimientos y composiciones para la inhibicion de resorcion osea.
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
GEP201706748B (en) Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
EA024702B8 (ru) Новые иммуномодуляторные и противовоспалительные соединения
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
UY31065A1 (es) Heterociclos ciclicos
MX367623B (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
MY148948A (en) Catecholamine derivatives and prodrugs thereof
IL198901A0 (en) Pyrimidine derivatives and multiple myeloma
EA200700601A1 (ru) Производные фениламинопиримидина как ингибиторы bcr-abl
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
WO2014106800A8 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
ATE435223T1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
MX341577B (es) Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero.